Laboratorios Farmaceuticos Rovi, S.A. (BME: ROVI)

ROVI Statistics

Total Valuation

Laboratorios Farmaceuticos Rovi has a market cap or net worth of EUR 3.22 billion. The enterprise value is 3.34 billion.

Market Cap	3.22B
Enterprise Value	3.34B

Important Dates

The last earnings date was Thursday, November 7, 2024.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	Jul 8, 2024

Share Statistics

Laboratorios Farmaceuticos Rovi has 51.15 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	51.15M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	22.14%
Float	18.61M

Valuation Ratios

The trailing PE ratio is 20.38 and the forward PE ratio is 18.67. Laboratorios Farmaceuticos Rovi's PEG ratio is 1.70.

PE Ratio	20.38
Forward PE	18.67
PS Ratio	4.21
PB Ratio	6.13
P/TBV Ratio	n/a
P/FCF Ratio	48.93
P/OCF Ratio	n/a
PEG Ratio	1.70

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.01, with an EV/FCF ratio of 50.75.

EV / Earnings	20.26
EV / Sales	4.18
EV / EBITDA	14.01
EV / EBIT	15.73
EV / FCF	50.75

Financial Position

The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.23.

Current Ratio	2.50
Quick Ratio	0.92
Debt / Equity	0.23
Debt / EBITDA	0.54
Debt / FCF	1.95
Interest Coverage	69.72

Financial Efficiency

Return on equity (ROE) is 29.65% and return on invested capital (ROIC) is 20.37%.

Return on Equity (ROE)	29.65%
Return on Assets (ROA)	15.55%
Return on Capital (ROIC)	20.37%
Revenue Per Employee	378,611
Profits Per Employee	78,162
Employee Count	2,111
Asset Turnover	0.94
Inventory Turnover	0.87

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +18.60% in the last 52 weeks. The beta is 0.51, so Laboratorios Farmaceuticos Rovi's price volatility has been lower than the market average.

Beta (5Y)	0.51
52-Week Price Change	+18.60%
50-Day Moving Average	72.06
200-Day Moving Average	79.11
Relative Strength Index (RSI)	31.17
Average Volume (20 Days)	122,973

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of EUR 799.25 million and earned 165.00 million in profits. Earnings per share was 3.09.

Revenue	799.25M
Gross Profit	488.92M
Operating Income	212.57M
Pretax Income	211.73M
Net Income	165.00M
EBITDA	233.89M
EBIT	212.57M
Earnings Per Share (EPS)	3.09

Balance Sheet

The company has 17.55 million in cash and 128.28 million in debt, giving a net cash position of -110.72 million or -2.16 per share.

Cash & Cash Equivalents	17.55M
Total Debt	128.28M
Net Cash	-110.72M
Net Cash Per Share	-2.16
Equity (Book Value)	558.19M
Book Value Per Share	10.28
Working Capital	332.34M

Cash Flow

In the last 12 months, operating cash flow was 126.18 million and capital expenditures -60.32 million, giving a free cash flow of 65.86 million.

Operating Cash Flow	126.18M
Capital Expenditures	-60.32M
Free Cash Flow	65.86M
FCF Per Share	1.29

Margins

Gross margin is 61.17%, with operating and profit margins of 26.60% and 20.64%.

Gross Margin	61.17%
Operating Margin	26.60%
Pretax Margin	26.49%
Profit Margin	20.64%
EBITDA Margin	29.26%
EBIT Margin	26.60%
FCF Margin	8.24%

Dividends & Yields

This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 1.78%.

Dividend Per Share	1.10
Dividend Yield	1.78%
Dividend Growth (YoY)	-14.69%
Years of Dividend Growth	4
Payout Ratio	34.21%
Buyback Yield	n/a
Shareholder Yield	1.78%
Earnings Yield	4.91%
FCF Yield	2.04%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Laboratorios Farmaceuticos Rovi has an Altman Z-Score of 9.95.

Altman Z-Score	9.95
Piotroski F-Score	n/a